Bio-link Australia Pty. Ltd.


Please find below a list of selected recent news and press releases from Bio-Link, our clients and the industry. Please select a specific news list for each source from the buttons on the left hand side.

19th September 2018 – Australia’s Back Yard Science Challenges the Pharma Industry

This week, “backyard science” was considered the next potential disruptor in the pharmaceutical industry, in a controversial article published in Trends in Biotechnology from CellPress Reviews, co-authored by Christopher Boyer, co-Executive Director of Bio-Link. The opinion piece reveals how community biolabs are popping up around the world to create innovative approaches to drug manufacturing. Their aim is to facilitate increased access to drugs for patients who cannot afford to pay high drug prices, and are willing to explore do-it-yourself or “DIY” manufacturing of medicines.

A prominent example of this potential coming wave of DIY medicines is the production of home-brewed insulin, for the treatment of diabetes. The Open Insulin Project, an initiative born out of California, brings together community biolabs around the world, who are focused on making the protocol for insulin production freely available. Unlike Australians who benefit from Government-subsidised medicines, patients in the US do not receive the same high level of reimbursement for drugs such as insulin. Many diabetics cannot afford to pay, and chose to go without the necessary medication. However, if the Project succeeds, pioneering patients could turn to home-brewed insulin to beat the high price of the drug.

In Australia, Sydney is home to a biolab community called BioFoundry, Australia’s first open-access molecular biology laboratory, offering everyday citizens the opportunity to collaborate in scientific research and development. Australia is well known to be a world leader in innovation, and these community biolabs offer non-scientists and early career scientists the opportunity to experiment in the lab to develop new medicines.

You can read more about DIY insulin and the DIYBio movement in the new Trends in Biotechnology article (here) and in a web synopsis published in The Conversation (here).

Please share our story and let us know your thoughts on DIY medicines. We’d love to hear opinions from our followers in Australia and around the world.

Bio-Link co-Executive Director, Christopher Boyer, presents at BioMelbourne Network’s Biotech Development Lab 2018

BioMelbourne Network held a symposium in August to explore how drug development, and the biotech and pharma sectors more broadly, are changing in the 21st century. Christopher Boyer spoke about commercial strategy approaches in his presentation entitled “De-risking preclinical assets with early human insights; recent advances in human tissue and disease models.” View the slides here.

Actinogen announces successful completion of interim analysis & $15m raise

Bio-Link client Actinogen Medical announced that an independent Data Safety and Monitoring Board completed a planned interim analysis of its phase II Alzheimer’s trial of Xanamem and recommended continuation of the trial without modification (link), together with a $15M placement by leading investors including biotechnology value fund (link). Learn more about Xanamem.

Christos Papadimitriou & Lilly Bojarski selected for 2018 Bridge Program

Bio-Link’s Christos Papadimitriou and Lilly Bojarski have been selected for the MTPCOnnect Bridge Program 2018, which offers strategic professional training to advance skills necessary to boost the commercialisation of Australian innovative research and biotechnologies. Bio-Link is pleased to be represented for a second year, following the inauguration of the initiative in 2017. Learn more about the program here.

4th January 2018 – Bio-Link Engaged by FivepHusion

Bio-Link has been engaged by FivepHusion Pty Ltd to assist with commercialisation of Deflexifol.  FivepHusion has developed Deflexifol, an innovative formulation of 5-FU and leucovorin, as a replacement for the current standard of care in solid tumour indications. A Phase II clinical in colorectal carcinoma trial is planned. To learn more about this opportunity, please click here.